HUYA Bioscience appoints John Ratliff as President and CEO

He was previously President/COO of Quintiles' Global Services organisation

HUYA Bioscience International has appointed John Ratliff as President and Chief Executive.

The move is part of the San Diego, CA, US-based firm's long-term growth plan. Founder Mireille Gillings continues as Executive Chair of its Board of Directors.

Ratliff brings more than 30 years of experience in the biopharmaceutical and information technology industries to the firm. He led Quintiles' Global Services organisation as President/COO with its clinical research, commercial, consulting, lab operations.

He also worked for Acterna, a provider of communications test solutions for telecommunications and cable network operators. Before moving to Acterna in 2000, he worked for 19 years at IBM.

You may also like

Research & Development

HUYA Bioscience and Zhongshan Technology Park form alliance

To accelerate discovery and development of biopharmaceuticals in China
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Subscribe now